文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

测序检测耐药对结核临床管理的影响评估

Evaluation of the Impact of a Sequencing Assay for Detection of Drug Resistance on the Clinical Management of Tuberculosis.
PubMed 文献 · Clin Infect Dis · 2019-01-01

加州公共卫生部自2012年起使用焦磷酸测序(PSQ)检测结核分枝杆菌对异烟肼、利福平、喹诺酮和注射类药物的耐药突变,并评估其对结核临床管理的影响。分析2012年8月至2016年12月监测与实验室数据,发现使用PSQ的耐多药结核患者有效治疗启动时间中位数为12天,未使用者为51天。调查显示部分临床医生因PSQ结果调整治疗方案,但部分患者存在可更早诊断的机会。

要点

  • PSQ用于痰沉淀标本可缩短耐多药结核有效治疗启动时间约5周。
  • 临床医生常依据PSQ结果调整结核治疗方案。
  • 应优先早期送检标本以最大化PSQ获益。

核心结论

  • 使用PSQ检测耐多药结核的患者比未使用者提前5周启动有效治疗。
  • 调查数据提示临床医生利用PSQ制定有效结核药物方案。

研究设计与样本

  • 分析2012年8月1日至2016年12月31日提交的结核监测和实验室数据,评估有效治疗启动时间。
  • 对临床医生进行问卷调查,评估PSQ结果对临床决策的影响。

主要发现

  • 共检测1957份标本,52%为沉淀标本,46%为培养分离株,提交时间中位数分别为采集后8天和35天。
  • 36例耐多药结核患者提交沉淀标本进行PSQ,从标本采集到耐多药结核治疗启动的中位时间为12天,未使用PSQ时为51天。
  • 303例患者返回完整调查,其中177例报告治疗改变,75名(42%)临床医生将PSQ列为改变原因。

临床怎么用

  • 对耐多药结核高风险且涂片阳性的患者,优先对沉淀标本进行PSQ检测以尽早启动有效治疗。
  • 临床医生可根据PSQ结果调整结核药物方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2012, the California Department of Public Health began using pyrosequencing (PSQ) to detect mutations associated with resistance to isoniazid, rifampin, quinolones and injectable drugs in Mycobacterium tuberculosis complex. We evaluated the impact of the PSQ assay on the clinical management of tuberculosis (TB) in California. METHODS: TB surveillance and laboratory data for specimens submitted 1 August 2012 through 31 December 2016 were analyzed to determine time to effective treatment initiation. A survey of clinicians was used to assess how PSQ results influenced clinical decision making. RESULTS: Of 1957 specimens tested with PSQ, 52% were sediments and 46% were culture isolates, submitted a median of 8 and 35 days, respectively, after collection. Among 36 patients with multidrug-resistant (MDR) TB who had a sediment specimen submitted for PSQ, median time from specimen collection to MDR-TB treatment initiation was 12 days vs 51 days when PSQ was not used. Completed surveys were returned for 303 patients, 177 of whom reported a treatment change; 75 (42%) of clinicians reported PSQ as a reason for change. Twenty-one patients either had an MDR-TB risk factor and a smear-positive sputum specimen, but had PSQ performed on a culture isolate (9/36 [25%]); or did not have PSQ used for MDR-TB diagnosis (12/38 [32%]) and thus had an opportunity for earlier MDR-TB diagnosis with PSQ on sediment. CONCLUSIONS: Patients with MDR-TB initiated effective treatment 5 weeks earlier when PSQ was used compared to those without PSQ. Survey data suggest clinicians use PSQ to devise effective TB drug regimens. To maximize the benefit of PSQ, earlier submission of specimens should be prioritized.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Lowenthal P, Lin SG, Desmond E, et al. Evaluation of the Impact of a Sequencing Assay for Detection of Drug Resistance on the Clinical Management of Tuberculosis. Clin Infect Dis. 2019. PMID: 30383209. doi:10.1093/cid/ciy937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。